3.22

6.67% -0.23

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $3.22, with a volume of 2.01M. It is down -6.67% in the last 24 hours and up +13.78% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Previous Close:

$3.45

Open:

$3.3

24h Volume:

2.01M

Relative Volume:

0.85

Market Cap:

$576.06M

Revenue:

$25.55M

Net Income/Loss:

$-341.97M

P/E Ratio:

-1.15

EPS:

-2.8

Net Cash Flow:

$-304.44M

1W Performance:

-4.17%

1M Performance:

+13.78%

6M Performance:

-31.63%

1Y Performance:

-58.85%

1-Day Range:

$3.194

$3.40

1-Week Range:

$3.194

$3.64

52-Week Range:

$1.775

$10.72

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1168)

Industry

Biotechnology (661)

Phone

617-370-8837

Address

399 BINNEY STREET, CAMBRIDGE

Employee

259

Twitter

Next Earnings Date

2025-02-21

Latest SEC Filings

RLAY's Discussions on Twitter

Compare RLAY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLAY Relay Therapeutics Inc	3.22	576.06M	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	455.45	115.69B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	529.24	53.25B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	307.99	39.22B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	577.89	35.78B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	269.63	27.68B	3.81B	-644.79M	-669.77M	-6.24

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-25	Initiated	Wells Fargo	Equal Weight
Sep-10-24	Resumed	Goldman	Buy
Sep-10-24	Upgrade	Jefferies	Hold → Buy
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

Jun 14, 2025

Relay Therapeutics’ SWOT analysis: AI-driven drug discovery stock faces pivotal phase - Investing.com India

Jun 14, 2025

Jun 12, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by California State Teachers Retirement System - Defense World

Jun 12, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News - GuruFocus

Jun 12, 2025

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar to Board of Directors - citybiz

Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com India

Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial By Investing.com - Investing.com South Africa

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar To Board Of Directors - marketscreener.com

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Bluefield Daily Telegraph

Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 9,293 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Jun 11, 2025

Jun 10, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025

Jun 09, 2025